![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 5
2022
Müller, Rüdiger B.; Schulze-Koops, Hendrik; Furst, Daniel E.; Cohen, Stanley B.; Kwok, Kenneth; Wang, Lisy; Killeen, Tim und Kempis, Johannes von
(2022):
Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
In: Clinical Rheumatology, Bd. 41, Nr. 4: S. 1045-1055
2019
Müller, Rüdiger B.; Hasler, Caroline; Popp, Florian; Mattow, Frederik; Durmisi, Mirsada; Souza, Alexander; Hasler, Paul; Rubbert-Roth, Andrea; Schulze-Koops, Hendrik und Kempis, Johannes von
(2019):
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts.
In: Journal of Clinical Medicine, Bd. 8, Nr. 10, 1548
Müller, Rüdiger B.; Späth, Michael; Restorff, Cord von; Ackermann, Christoph; Schulze-Koops, Hendrik und Kempis, Johannes von
(2019):
Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol.
In: Journal of Clinical Medicine, Bd. 8, Nr. 3, 302
Kempis, Johannes von; Duetsch, Sabine; Reuschling, Nicola; Villiger, Rahel; Villiger, Peter M.; Vallelian, Florencee; Schär, Dominik J. und Müller, Rüdiger B.
(2019):
Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland.
In: Swiss Medical Weekly, Bd. 149, w20022
2017
Müller, Rüdiger B.; Reshiti, Nazim; Kägi, Toni; Finckh, Axel; Haile, Sarah R.; Schulze-Koops, Hendrik; Schiff, Michael; Späth, Michael und Kempis, Johannes von
(2017):
Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM).
In: Clinical Rheumatology, Bd. 36, Nr. 1: S. 59-66